** Shares in Vitrolife VITR.ST plummet about 10% to nearly
eight-month low after the Swedish medical technology group's
margin declined in the final quarter urn:newsml:reuters.com:*:nFWN2UR0MC
** The company posts Q4 EBITDA margin of 16% versus 43%
reported a year ago
** "Most or all companies with a relatively high valuation
tend to be exposed when organic growth is temporary under
pressure. Especially when this also goes for the margins,"
Redeye analyst Johan Unnerus says
** The stock is bottom performer on STOXX 600 .STOXX
index, down over 38% year-to-date
(Reporting by Marta Frackowiak)
((marta.frackowiak@thomsonreuters.com))